# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
1 | 08-12-2024 | 06-30-2024 | 10-Q | |
2 | 05-08-2024 | 03-31-2024 | 10-Q | |
3 | 03-13-2024 | 12-31-2023 | 10-K |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Indaptus Therapeutics (NASDAQ:INDP) reported quarterly losses of $(0.47) per share which beat the analyst consensus estimate of...
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Indaptus Therapeutics (NASDAQ:INDP) with a Buy and maintains $...
Indaptus Therapeutics, Inc, (NASDAQ:INDP), a clinical stage biotechnology company dedicated to pioneering innovative cancer and...
Latest data from first and second cohorts support Company's 'pulse-prime' approach, demonstrating rapid clearance, ...
Indaptus Therapeutics, Inc, (NASDAQ:INDP), a clinical stage biotechnology company dedicated to pioneering innovative cancer and...